Ali Samiian has joined Cala Health as Head of Reimbursement and Healthcare Economics


Ali Samiian

Ali joins the Cala Health team after 15 years of working in the pharmaceutical and medical device industry. He has progressively and consistently held roles with increased responsibility and scope.  Ali’s special skills include leadership in the US and Global market access, sales, and strategic planning. Ali previously was the Director of US Market Access at Abbott. Prior to Abbott, Ali worked at Eurmea, Novartis, and as a Senior Policy Advisor to the Minister of Health in Ontario.
Welcome to The Cala Health Team. Ali!

Cala Health

Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its vertically integrated commercial model is reshaping the delivery of prescription therapies. Cala Health’s lead product, Cala Trio™, is the only non-invasive prescription therapy for essential tremor. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.

Learn more at